Aditxt (ADTX) Competitors $0.52 -0.08 (-13.84%) As of 11:57 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ADTX vs. CYCC, CMMB, PHIO, FLGC, IMNN, COCP, TXMD, MRKR, SLXN, and SNSEShould you be buying Aditxt stock or one of its competitors? The main competitors of Aditxt include Cyclacel Pharmaceuticals (CYCC), Chemomab Therapeutics (CMMB), Phio Pharmaceuticals (PHIO), Flora Growth (FLGC), Imunon (IMNN), Cocrystal Pharma (COCP), TherapeuticsMD (TXMD), Marker Therapeutics (MRKR), Silexion Therapeutics (SLXN), and Sensei Biotherapeutics (SNSE). These companies are all part of the "pharmaceutical products" industry. Aditxt vs. Its Competitors Cyclacel Pharmaceuticals Chemomab Therapeutics Phio Pharmaceuticals Flora Growth Imunon Cocrystal Pharma TherapeuticsMD Marker Therapeutics Silexion Therapeutics Sensei Biotherapeutics Aditxt (NASDAQ:ADTX) and Cyclacel Pharmaceuticals (NASDAQ:CYCC) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, earnings, dividends, analyst recommendations, risk, valuation and institutional ownership. Which has better earnings and valuation, ADTX or CYCC? Cyclacel Pharmaceuticals has higher revenue and earnings than Aditxt. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAditxt$12.05K213.93-$34.45MN/AN/ACyclacel Pharmaceuticals$40K360.64-$11.21M-$839.58-0.01 Does the media refer more to ADTX or CYCC? In the previous week, Aditxt had 2 more articles in the media than Cyclacel Pharmaceuticals. MarketBeat recorded 2 mentions for Aditxt and 0 mentions for Cyclacel Pharmaceuticals. Aditxt's average media sentiment score of 0.95 beat Cyclacel Pharmaceuticals' score of 0.00 indicating that Aditxt is being referred to more favorably in the media. Company Overall Sentiment Aditxt Positive Cyclacel Pharmaceuticals Neutral Which has more volatility & risk, ADTX or CYCC? Aditxt has a beta of 1.48, suggesting that its share price is 48% more volatile than the S&P 500. Comparatively, Cyclacel Pharmaceuticals has a beta of 0.15, suggesting that its share price is 85% less volatile than the S&P 500. Do analysts rate ADTX or CYCC? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aditxt 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00Cyclacel Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do insiders & institutionals hold more shares of ADTX or CYCC? 15.5% of Aditxt shares are held by institutional investors. Comparatively, 23.6% of Cyclacel Pharmaceuticals shares are held by institutional investors. 0.0% of Aditxt shares are held by insiders. Comparatively, 51.2% of Cyclacel Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Is ADTX or CYCC more profitable? Cyclacel Pharmaceuticals has a net margin of 0.00% compared to Aditxt's net margin of -206,431.38%. Aditxt's return on equity of -316.98% beat Cyclacel Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Aditxt-206,431.38% -316.98% -80.88% Cyclacel Pharmaceuticals N/A -723.64%-145.51% SummaryCyclacel Pharmaceuticals beats Aditxt on 7 of the 12 factors compared between the two stocks. Get Aditxt News Delivered to You Automatically Sign up to receive the latest news and ratings for ADTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ADTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADTX vs. The Competition Export to ExcelMetricAditxtMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.57M$2.61B$6.06B$10.38BDividend YieldN/A57.77%5.73%4.78%P/E RatioN/A23.1786.0626.86Price / Sales213.93615.09582.90180.66Price / CashN/A25.7125.7330.17Price / Book-0.345.3112.686.63Net Income-$34.45M$32.78M$3.31B$276.12M7 Day Performance-24.46%0.79%-0.66%-1.86%1 Month Performance-48.71%9.27%8.45%5.63%1 Year Performance-99.82%-0.54%77.27%32.94% Aditxt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADTXAditxtN/A$0.52-13.8%N/A-99.8%$2.57M$12.05K0.0060Gap UpCYCCCyclacel Pharmaceuticals0.1323 of 5 stars$6.44-4.9%N/A-96.6%$14.43M$40K-0.0114High Trading VolumeCMMBChemomab Therapeutics2.9242 of 5 stars$2.87+5.5%$26.50+823.3%-27.4%$14.07MN/A-1.2220Analyst UpgradeGap DownPHIOPhio Pharmaceuticals2.4396 of 5 stars$2.36-1.3%$14.00+493.2%-17.9%$13.69MN/A-0.7310FLGCFlora Growth2.6367 of 5 stars$19.77+4.2%$93.00+370.4%-78.4%$13.51M$59.51M-0.58280Gap UpIMNNImunon2.484 of 5 stars$5.23-2.6%$232.50+4,345.5%-66.9%$13.10M$500K-0.4030COCPCocrystal Pharma1.6112 of 5 stars$1.22+0.8%$6.00+391.8%-34.7%$12.43MN/A-0.9810TXMDTherapeuticsMD0.599 of 5 stars$1.05-2.1%N/A-34.2%$12.41M$2.56M0.00420Negative NewsGap UpHigh Trading VolumeMRKRMarker Therapeutics3.9674 of 5 stars$1.08+13.1%$13.17+1,119.1%-62.7%$12.35M$6.59M-0.7960High Trading VolumeSLXNSilexion Therapeutics2.1728 of 5 stars$3.87-1.5%$75.00+1,838.0%-89.9%$12.29MN/A0.00N/ASNSESensei Biotherapeutics4.4321 of 5 stars$9.55flat$55.00+475.9%+19.8%$12.05MN/A-0.4540Gap Up Related Companies and Tools Related Companies Cyclacel Pharmaceuticals Alternatives Chemomab Therapeutics Alternatives Phio Pharmaceuticals Alternatives Flora Growth Alternatives Imunon Alternatives Cocrystal Pharma Alternatives TherapeuticsMD Alternatives Marker Therapeutics Alternatives Silexion Therapeutics Alternatives Sensei Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADTX) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aditxt, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aditxt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
